Skip to content
DraconiticResearch
Search Sources API
201,683 studies31 sourcesUpdated 2 min ago
Peer-reviewedCC BY 4.0Med-X

Bioengineering strategies for off-the-shelf, cell-based cancer immunotherapy

  • Brendan R. Barlow1,2,3
  • Ana M. Sandoval-Castellanos2,3,4
  • Robert J. Canter2
  • Jinhwan Kim1,2,3
4 affiliations
  1. 1Department of Biomedical Engineering, University of California Davis, Davis, CA 95616 USA
  2. 2Department of Surgery, School of Medicine, University of California Davis, Sacramento, CA 95817 USA
  3. 3Center for Bioengineering in Medicine, School of Medicine, University of California Davis, Sacramento, CA 95817 USA
  4. 4Department of Ophthalmology and Vision Science, School of Medicine, University of California Davis, Sacramento, CA 95817 USA
Read full textPDFDOICite

Abstract

Cancer immunotherapy has reshaped modern oncology by leveraging immune effector cells to recognize and eliminate malignant tissues. Among cell-based approaches, adoptive cell therapies, most prominently chimeric antigen receptor (CAR) T cells, have produced high response rates and deep remissions in several hematologic malignancies. Despite these clinical successes, broad deployment remains limited by the dominant autologous manufacturing paradigm, which is associated with high per patient cost, prolonged vein to vein time, and heterogeneity in starting material and final product quality, particularly in heavily pretreated patients. Off-the-shelf strategies aim to improve scalability and access by standardizing either the cellular input, such as donor derived or renewable sources, or the engineering reagent used to program immune cells. Here, we review bioengineering approaches enabling three complementary off-the-shelf platforms, including allogeneic CAR T cells, natural killer and invariant natural killer T cell-based therapies, and in vivo CAR generation. Lastly, we outline the clinical translation outlook for off-the-shelf cell therapy, highlighting current limitations and future bioengineering and manufacturing directions. Together, these approaches highlight convergent design principles that will shape the next generation of broadly accessible cell-based cancer immunotherapies, including immune compatibility, controllable activation, and manufacturability.

Graphical Abstract:

Related

  1. Bioengineering strategies to enhance BCG immunotherapy against bladder cancer
    Senhao Li, Haige Chen, Bing Feng
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textSurgery & anaesthesiaCrossrefEurope PMC
  2. Antibody‒cell conjugates: A novel "off-the-shelf" modality bridging ADCs and CAR-T for cancer immunotherapy.
    Yifei Dai, Yujia Xie, Xiaojuan Ma +5
    Acta pharmaceutica Sinica. BPeer-reviewedCC BY-NC-NDFull textOncologyEurope PMCPMC
  3. Therapeutic Strategies After Immunotherapy Failure in Advanced Non-Small Cell Lung Cancer: Mechanisms of Resistance and Emerging Treatment Approaches
    Masatoshi Kanayama, Masaru Takenaka, Hidetaka Uramoto
    CancersPeer-reviewedCC BY 4.0OncologyCrossref
  4. Molecular mechanisms and therapeutic strategies of immunotherapy resistance in esophageal cancer
    Yiqian Pang, Panpan Jiang, Ke Liu +6
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textOncologyCrossrefEurope PMC
  5. Gastric cancer peritoneal metastases as an immune compartment: immune evasion, systemic immunotherapy and regional treatment strategies
    Eoghan Burke
    Frontiers in OncologyPeer-reviewedCC BY 4.0Full textSurgery & anaesthesiaCrossrefEurope PMCEurope PMCPMC

Cite

BibTeXRIS
BibTeX
@article{barlow2026bioengineering,
  title = {{Bioengineering strategies for off-the-shelf, cell-based cancer immunotherapy}},
  author = {Brendan R. Barlow and Ana M. Sandoval-Castellanos and Robert J. Canter and Jinhwan Kim},
  journal = {Med-X},
  year = {2026},
  month = nov,
  doi = {10.1007/s44258-026-00099-1},
  url = {https://doi.org/10.1007/s44258-026-00099-1},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Bioengineering strategies for off-the-shelf, cell-based cancer immunotherapy
AU  - Brendan R. Barlow
AU  - Ana M. Sandoval-Castellanos
AU  - Robert J. Canter
AU  - Jinhwan Kim
PY  - 2026
DA  - 2026/11/05
JO  - Med-X
DO  - 10.1007/s44258-026-00099-1
UR  - https://doi.org/10.1007/s44258-026-00099-1
AB  - Cancer immunotherapy has reshaped modern oncology by leveraging immune effector cells to recognize and eliminate malignant tissues. Among cell-based approaches, adoptive cell therapies, most prominently chimeric antigen receptor (CAR) T cells, have produced high response rates and deep remissions in several hematologic malignancies. Despite these clinical successes, broad deployment remains limited by the dominant autologous manufacturing paradigm, which is associated with high per patient cost, prolonged vein to vein time, and heterogeneity in starting material and final product quality, particularly in heavily pretreated patients. Off-the-shelf strategies aim to improve scalability and access by standardizing either the cellular input, such as donor derived or renewable sources, or the engineering reagent used to program immune cells. Here, we review bioengineering approaches enabling three complementary off-the-shelf platforms, including allogeneic CAR T cells, natural killer and invariant natural killer T cell-based therapies, and in vivo CAR generation. Lastly, we outline the clinical translation outlook for off-the-shelf cell therapy, highlighting current limitations and future bioengineering and manufacturing directions. Together, these approaches highlight convergent design principles that will shape the next generation of broadly accessible cell-based cancer immunotherapies, including immune compatibility, controllable activation, and manufacturability.  Graphical Abstract:
SN  - 2731-8710
ER  -